The company is currently conducting a Phase II trial of ICT-107, which is a study in patients with newly diagnosed glioblastoma.
ImmunoCellular anticipates reporting interim safety analysis data in the first quarter of 2013. Afterwards, the company expects the final safety and efficacy results late in the second half of 2013.
According to John. S. Yu, MD, ImmunoCellular's Interim Chief Executive Officer:
“We believe that ICT-107 represents the next generation of cancer immunotherapy by targeting both tumor cells and cancer stem cells with a dendritic cell-based vaccine. We deeply appreciate the oncology community's enthusiasm for the ICT-107 clinical program and their shared interest in exploring the therapeutic potential of this potentially breakthrough technology, as reflected in the pace of enrollment in the trial. I congratulate the ImmunoCellular clinical team for this successful milestone in efficiently and rapidly completing enrollment in this complex clinical trial.”
Dr. John Boockvar, director of the Brain Tumor Research Group, associate professor of neurological surgery at Weill Cornell Medical College and a neurosurgeon at NewYork-Presbyterian Hospital/Weill Cornell Medical Center remarked:
“This potential vaccine tested in patients with Stage IV glioblastoma is designed to leverage the patient's own immune system after surgery and chemo-radiation treatments to hunt and destroy remaining brain tumor cancer cells - one of the clinical trial testing sites for the experimental vaccine. Previous Phase I study results show the vaccine may improve patient survival by enabling them to remain disease-free longer when the vaccine is combined with standard treatments. I look forward to seeing the Phase II results.”
On IMUC’s chart, the relative Strength Index (RSI) has turned bullish. The Moving Average Convergence/Divergence has also turned bullish. It appears that Immuno may be close to breaking out, and additional buy-side volume could take the stock to near the $2.65 level, perhaps even higher to the $2.80 range. In yesterday's trading session, the stock filled a gap around $2.40. With the company's near term catalyst approaching shortly, we see ImmunoCellular Therapeutics offering good upside potential.
Immune therapies could end up being the next standard for cancer treatments, so ImmunoCellular Therapeutics is one to keep a close eye on.